Top Markets
#1 WYDE: End Hunger WYDE: End Hunger +2.71%
#2 MetaDAO MetaDAO +2.37%
#3 StonkBroker StonkBroker +2.30%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +2.27%
#5 PulseX PulseX +1.94%
#6 The Grays Currency The Grays Currency +1.93%
#7 Dual Dual +1.86%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +1.67%
#9 Fractal Bitcoin Fractal Bitcoin +1.59%
#10 Wrapped Pulse Wrapped Pulse +1.56%
Coin of the day
WYDE: End Hunger WYDE: End Hunger
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Adagene Inc. Adagene Inc.

Adagene Inc.

ADAG
Classement en actions #19938
Adagene Inc. functions as a clinical-stage biopharmaceutical organization,... Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Prix de l'action
$3.88
Capitalisation boursière
$146.08M
Changement (1 jour)
-0.51%
Changement (1 an)
65.11%
Pays
CN
Échange Adagene Inc. (ADAG)

Catégorie

Healthcare
Revenus pour Adagene Inc. (ADAG)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Adagene Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Adagene Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH